Delayed Liver Function Impairment Secondary to Interferon β-1a Use in Multiple Sclerosis.

about

Delayed Liver Function Impairment Secondary to Interferon β-1a Use in Multiple Sclerosis.

Item

http://www.wikidata.org/entity/Q41857200

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Delayed Liver Function Impairment Secondary to Interferon β-1a Use in Multiple Sclerosis.

@en

type

Item

label

Delayed Liver Function Impairment Secondary to Interferon β-1a Use in Multiple Sclerosis.

@en

prefLabel

Delayed Liver Function Impairment Secondary to Interferon β-1a Use in Multiple Sclerosis.

@en

P1476

Delayed Liver Function Impairment Secondary to Interferon β-1a Use in Multiple Sclerosis.

@en

P2093

Lin Chun-Yen

http://www.w3.org/2001/XMLSchema#string

Lyu Rong-Kuo

http://www.w3.org/2001/XMLSchema#string

Ming-Feng Liao

http://www.w3.org/2001/XMLSchema#string

Su-Chen Yen

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Revised diagnostic criteria for neuromyelitis optica.

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.

Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.

Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.

Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study.

P304

130-134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1159/000354042

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

254261883

http://www.w3.org/2001/XMLSchema#string

P698

23904853

http://www.w3.org/2001/XMLSchema#string

P932

3728605

http://www.w3.org/2001/XMLSchema#string